Compare VTS & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTS | CTMX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.0M | 716.9M |
| IPO Year | 2022 | 2015 |
| Metric | VTS | CTMX |
|---|---|---|
| Price | $17.97 | $2.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $21.50 | $12.25 |
| AVG Volume (30 Days) | 375.2K | ★ 2.9M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 9.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,989,000.00 | $76,201,000.00 |
| Revenue This Year | $26.85 | N/A |
| Revenue Next Year | N/A | $1.24 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ 13.22 | N/A |
| 52 Week Low | $15.00 | $2.20 |
| 52 Week High | $22.91 | $8.21 |
| Indicator | VTS | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 59.31 | 41.37 |
| Support Level | $17.33 | $2.20 |
| Resistance Level | $18.61 | $3.93 |
| Average True Range (ATR) | 0.38 | 0.15 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 69.52 | 45.74 |
Vitesse Energy Inc is an independent energy company focused on returning capital to stockholders through owning interests as a non-operator in oil and natural gas wells. It is engaged in the acquisition, development, and production of non-operated oil and natural gas properties in the United States that are generally operated by oil companies and are in the Williston Basin of North Dakota and Montana with limited operations. The company also have properties in the Central Rockies, including the Denver-Julesburg Basin and the Powder River Basin.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.